Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Thirunavukkarasu Angappan: What mRNA Manufacturing Teaches Us About Scaling Hemophilia Gene Therapy
Thirunavukkarasu Angappan/LinkedIn
Aug 14, 2026, 16:24

Thirunavukkarasu Angappan: What mRNA Manufacturing Teaches Us About Scaling Hemophilia Gene Therapy

Thirunavukkarasu Angappan, Vice President of Operations and Manufacturing at PopVax, shared a post on LinkedIn:

”What mRNA Manufacturing Teaches Us About Scaling Hemophilia Gene Therapy

Hemgenix costs 3.5 million dollar per dose.

Roctavian, 2.9 million dollar. One treatment, one lifetime, one very fragile factory.

  • Vector manufacturing alone can cost 3–7 million dollar per 500L batch — and a single batch may only treat 2–3 adult hemophilia B patients.
  • The industry still lacks a standardized, commercial-scale AAV/LNP manufacturing platform equivalent to what exists for monoclonal antibodies.
  • The choice of upstream platform — transient HEK293 transfection vs. stable producer cell lines — remains the single most consequential, unresolved manufacturing decision in the field.

This is almost exactly the standardisation gap mRNA/LNP manufacturing faced in 2021 — proven at lab scale, unproven at commercial scale, every developer solving the same problems independently.

Having lived through that phase with mRNA, I’d bet gene therapy manufacturers are about to relearn several of the same lessons the hard way.

Will AAV gene therapy manufacturing repeat mRNA’s early growing pains — or has the industry actually absorbed that lesson this time?”

Thirunavukkarasu Angappan: What mRNA Manufacturing Teaches Us About Scaling Hemophilia Gene Therapy

Stay updated with Hemostasis Today.

Gene therapy Health Hematology Hemophilia Hemostasis Hemostasis News Hemostasis Today Medicine mRNA Thirunavukkarasu Angappan
NewsFeed